联合疗法在炎症性肠病中的应用进展  

Research progress on combination therapy in inflammatory bowel disease

作　　者：彭雯[1,2] 罗超[1] 孙志广[1,2] PENG Wen;LUO Chao;SUN Zhiguang(Department of Spleen and Stomach,The Second Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210017;Nanjing University of Chinese Medicine,China)

机构地区：[1]南京中医药大学第二附属医院脾胃科,江苏南京210017 [2]南京中医药大学

出　　处：《胃肠病学和肝病学杂志》2024年第2期214-217,共4页Chinese Journal of Gastroenterology and Hepatology

基　　金：国家自然科学基金青年科学基金项目(82104792);江苏省第二中医院中青年科技菁英项目(SEZJY2023014);南京中医药大学自然科学基金项目(XZR2023067)。

摘　　要：炎症性肠病(inflammatory bowel disease,IBD)是一种难治性肠道炎症性疾病,药代动力学的失效及药效学逃逸导致目前以单一靶向治疗为主的方案受到限制,而对于重症及肠外表现的治疗不尽如人意,加速了人们研究联合疗法的进度,既往比较成熟的联合治疗案例进一步推动双靶向治疗方案的研究,该文就IBD联合疗法作一概述。Inflammatory bowel disease(IBD)is a refractory intestinal inflammatory disease,the failure of pharmacokinetics and pharmacodynamic evasion has led to the current single-targeted therapy based treatment is restricted,and the unsatisfactory treatment of severe and extraparenteral manifestations has accelerated the progress of research on combination therapy.The previous mature combination therapy cases have further promoted the research of dual-targeted therapy regimens.This article reviewed the combination therapy for IBD.

关 键 词：炎症性肠病 联合疗法 双靶向治疗 

分 类 号：R574.62[医药卫生—消化系统]